Navigation Links
Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia
Date:4/23/2014

Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat acute myeloid leukemia (AML) are very promising. Patients treated with CPX-351, a combination of the chemotherapeutic drugs cytarabine and daunorubicin, are showing better responses than patients treated with the standard drug formulation.

"Acute myeloid leukemia is an aggressive blood cancer with very low rates of treatment success, especially in older patients," explained Jeffrey Lancet, M.D., senior member of the Department of Malignant Hematology and chief of the Leukemia Section at Moffitt.

AML is diagnosed in approximately 19,000 people in the United States each year and results in over 10,000 deaths annually. Many patients with AML are older and have additional medical conditions, which makes treatment difficult. Only 50 percent of patients respond to existing therapies and the average survival time is less than 1 year. Therefore, researchers are trying to find new treatment options to increase survival.

The phase 2 study included 126 newly diagnosed AML patients from 18 cancer centers across the United States and Canada. The patients received the standard chemotherapeutic agents, cytarabine and daunorubicin, or the novel drug combination CPX-351.

"Patients with AML who received CPX-351 had a higher likelihood of remission than patients who received standard chemotherapy," said Lancet, who is the principal investigator and lead author of this study. "In addition, CPX-351 led to longer survival in the large subset of patients whose AML arose out of a previously diagnosed hematologic disorder, such as myelodysplastic syndrome."

Scientists know that cytarabine and daunorubicin work best in a particular concentration ratio. Unfortunately, it is difficult to maintain that ratio in the body when the drugs are administered; therefore, they don't work as effectively as they could. The drug CPX-351 is composed of substances called lipids. Lipids make up the outer membrane of cells and can form hollow spheres or vesicles that can be filled with drugs. Cytarabine and daunorubicin are present inside the CPX-351 lipid vesicle in a fixed ratio that is known to work most effectively.

"The results from this study show a high degree of activity in AML, leading to the opening of the new, larger randomized phase 3 study, which will definitively determine whether CPX-351 is superior to standard chemotherapy," said Lancet.


'/>"/>
Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt researchers find cancer therapies affect cognitive functioning among breast cancer survivors
2. Moffitt Cancer Center researchers: Quality of life as important as quantity of life
3. Moffitt Cancer Center researchers working at frontiers of melanoma research
4. Moffitt researchers find adolescents with cancer concerned about their future reproductive health
5. Moffitt researcher publishes book on nutritional management of cancer treatment effects
6. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
7. Researchers creating designer lymph nodes based on Moffitts Total Cancer Care initiative
8. Moffitt Cancer Center researchers identify drivers of sarcoma growth and survival
9. Moffitt Cancer Center researchers develop and test new anti-cancer vaccine
10. Moffitt researcher, colleagues find success with new immune approach to fighting some cancers
11. Moffitt researchers: Darwins principles say cancer will always evolve to resist treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , ... February 24, 2017 , ... ... into the Senior International Elite division on February 12th. Ms. Esparza qualified ... at the elite qualifier competition held in Las Vegas, Nevada. Frida is one ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... an official 2017 partnership with The Jensie Gran Fondo of Marin. For the ... UVB rays with Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled to provide ...
(Date:2/23/2017)... ... February 23, 2017 , ... The 89th Academy Awards will be celebrated this ... Education Policy Center Bunkum Award. We invite you to enjoy our 11th annual tongue-in-cheek ... winner is the Center for American Progress (CAP), for its report, Lessons From State ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... clinician-based audience, will be participating in Rare Disease Day events, hosted by the ... addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, will be ...
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, ... June: From Not to Hot,” which will begin airing on February 24, 2017. The ... millions from the 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb 23, 2017 Research and ... Price Analysis and Strategies - 2016" report to their offering. ... The latest ... drug pricing data and benchmarks in the global Oesophageal Cancer market. ... What are the key drugs marketed for Oesophageal Cancer ...
(Date:2/23/2017)... Regulus Therapeutics Inc . (Nasdaq: RGLS), ... innovative medicines targeting microRNAs, today announced it will release ... Thursday, March 2, 2017 after the market closes. ... on March 2, 2017 at 5:00 p.m. Eastern Time ... results and provide a general business update.  A live ...
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... & Trends - Industry Forecast to 2025" report to their ... The ... around 6.9% over the next decade to reach approximately $47.6 billion ... estimates and forecasts for all the given segments on global as ...
Breaking Medicine Technology: